Latest European Union News

Page 1 of 27
Cann Group says its balance-sheet repair and cost cuts have created room for growth, with September-quarter revenue and exports jumping. But the medicinal cannabis producer remains loss-making on a normalised basis and is now under pressure to turn improving sales into consistently positive cash flow.
Ada Torres
Ada Torres
18 Nov 2026
Moderna returned to quarterly GAAP profit, raised its 2026 revenue growth outlook and reported positive Phase 3 melanoma data. The stronger quarter was supported by international COVID vaccine sales, while cash generation and pipeline execution remain important tests.
Ada Torres
Ada Torres
6 Nov 2026
ClearVue Technologies has converted its Canva project into a binding subcontract and secured certifications that broaden the market for its solar glass. But the ASX-listed company ended Q1 FY27 with A$2.281 million in cash, A$2.666 million of quarterly operating outflows and estimated funding for just 1.3 quarters.
Victor Sage
Victor Sage
30 Oct 2026
Alterity Therapeutics says it has begun operational preparations for a Phase 3 ATH434 trial after FDA minutes confirmed the proposed design and registrational pathway in Multiple System Atrophy. The company ended September with A$41.3 million in cash, while a new US patent extends protection for ATH434 to 2045.
Ada Torres
Ada Torres
30 Oct 2026
Clinuvel has submitted NEURACTHEL Instant for regulatory review in three initial European Union markets, opening a potential pathway for its second pharmaceutical product. The decentralised review is expected to take 300 days, excluding clock stops, but the product is not yet approved anywhere.
Victor Sage
Victor Sage
30 Oct 2026
Control Bionics has begun converting its expanded product and regulatory pipeline into revenue, while a completed $9.75 million capital raising gives the company a larger cash buffer. The next test is whether partner-led sales and NeuroStrip trial conversions can reduce its cash burn as planned.
Victor Sage
Victor Sage
29 Oct 2026
Everest Metals’ Mt Edon project has been selected as Australia’s representative site in a five-year German-funded exploration program and accepted into the European Union’s Raw Materials Mechanism. The recognition may improve access to technical expertise, strategic partners and potential financing, although no funding, offtake or development commitment was announced.
Maxwell Dee
Maxwell Dee
26 Oct 2026
Starpharma has submitted its European trial application for DEP HER2-Lu and completed manufacture of clinical material, bringing its lead radiopharmaceutical closer to first patient dosing. The biotech also took control of Petalion, collected a Radiopharm option fee and finished the quarter with AUD $34.4 million in cash.
Ada Torres
Ada Torres
22 Oct 2026
Orthocell’s flagship Remplir nerve-repair product gained ground in the US and Thailand during the September quarter, even as total revenue slipped from the June period. The company reported A$39 million in available funds and said it does not currently expect to raise additional capital.
Ada Torres
Ada Torres
22 Oct 2026
Algorae has secured exclusive Australian commercial rights across eight Umedica-branded molecules while separately advancing a Umedica-supplied product towards regulatory approval. The broader arrangement remains partly non-binding, with financial terms undisclosed and TGA approval still pending.
Victor Sage
Victor Sage
19 Oct 2026
Neometals has cut its annual loss and sharpened its portfolio, but Deloitte has warned of a material uncertainty over the company’s ability to continue as a going concern. The miner says it may need about A$5 million in additional funding from December while pursuing unpaid placement proceeds from Omaha Value Holdings.
Victor Sage
Victor Sage
16 Oct 2026
Medical Developments International CEO Brent MacGregor is stepping down after six years, with CFO Anita James taking over as interim CEO from 15 October. The board has begun searching for a permanent successor as MacGregor prepares to return to North America.
Ada Torres
Ada Torres
15 Oct 2026

Browse the archive

Full archive